Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement
Author:
- 6 February 2013
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 7 (3) , 169-182
Abstract
Despite remarkable advances in identifying and managing coronary heart disease, the global burden of cardiovascular (CV) risk and levels of undetected, subclinical heart disease remain enormous. Substantial numbers of patients do not reach their therapeutic goals, others are unable to tolerate the treatments, half may fail to adhere to their programs, and in those who do attain their targets, major cardiovascular events may continue. Well-known risk factors, such as obesity and diabetes, have now gained the upper hand, with no evidence-based remedy capable of reversing this trend. All told, less than 1% of American adults and adolescents qualify for ideal CV health; world-wide, the growing prevalence of CV risk factors in children is imposing. A number of novel emerging drug therapies are in development, some recently approved for use in patients with familial hypercholesterolemia. Hopefully, they will contribute significantly to the current therapeutic armamentarium. However, for meaningful improvement in total and residual CV risk, an optimal mix of all available modalities will likely be necessary, including earlier and more effective prevention, aggressive medical care, revascularization and device implantation, judicious use of novel agents, and reengineering of the environment.Keywords
This publication has 78 references indexed in Scilit:
- Molecular mechanisms of vascular effects of High‐density lipoprotein: alterations in cardiovascular diseaseEMBO Molecular Medicine, 2012
- The rise of cardiovascular medicineEuropean Heart Journal, 2012
- Lifetime Risks of Cardiovascular DiseaseNew England Journal of Medicine, 2012
- Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin TherapyNew England Journal of Medicine, 2011
- Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery diseaseJournal of Clinical Investigation, 2011
- The Evolving Role of HDL in the Treatment of High-Risk Patients with Cardiovascular DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2011
- Lifetime Risks for Cardiovascular Disease Mortality by Cardiorespiratory Fitness Levels Measured at Ages 45, 55, and 65 Years in MenJACC, 2011
- Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patientsJournal of Lipid Research, 2008
- Effects of Torcetrapib in Patients at High Risk for Coronary EventsNew England Journal of Medicine, 2007
- HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular EventsNew England Journal of Medicine, 2007